Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BL1107 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BL1107 is sterile ophthalmic solution to be administered at varying concentrations | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BL1107 | DRUG | BL1107 topical ocular solution |
Inclusion Criteria: * Documented diagnosis of dry eye disease * Conjunctival hyperemia in both eyes, without clinical signs of infection or allergic conjunctivitis Exclusion Criteria: * Any active ocular disease * Anticipated wearing of contact lenses during study Additional criteria per protoco...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 2 | PHASE3 | ABBV-444, REFRESH OPTIVE UD |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | VSJ-110 |
| Oculis Holding AG | OCS | 1 | PHASE2 | licaminlimab |
| Alcon AG | ALC | 1 | N/A | Undisclosed |
| Harrow, Inc. | HROW | 1 | - | Undisclosed |
BL1107 is an investigational small molecule being developed for the treatment of Dry Eye Disease. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is being studied in a clinical trial to evaluate its effects on hyperemia resolution in patients with dry eye.
BL1107 is being developed by Bausch Health Companies Inc., a company traded on the New York Stock Exchange under the ticker symbol BHC. The company is conducting clinical research to evaluate the safety and efficacy of this investigational drug for Dry Eye Disease.
BL1107 is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The drug is being studied in an ongoing clinical trial to assess its potential as a treatment for Dry Eye Disease.
BL1107 is being studied in a Phase 2 clinical trial registered as NCT07778888, titled 'BL1107 Response and Intensity Guided Dosing for Hyperemia Resolution Trial.' This trial is not yet recruiting and plans to enroll 20 participants with Dry Eye Disease. The study is uncontrolled and open-label.
BL1107 is a small molecule designed to address Dry Eye Disease. While the specific molecular target has not been disclosed, the drug is being investigated for its ability to resolve hyperemia, which is a common symptom of dry eye. The ongoing Phase 2 trial will help determine its mechanism of action.